The Omicron variant of COVID-19 has the potential to push a world that is limping out of the damage caused by the Delta variant back into turmoil. Omicron was first reported in South Africa on 24 November, and subsequently the World Health Organization warned that the new variant was spreading faster than the Delta variant not only in South Africa, where the incidence of Delta is relatively lower, but also in countries such as the United Kingdom (UK), where the incidence of Delta is higher. Omicron has the potential to become the dominant variant in multiple European countries, including the UK, over the course of this week.
There is speculation regarding the emergence and spread of the mutation in South Africa. A prominent hypothesis is that the new variant evolved in the body of an immuno-compromised HIV patient. With vaccination rates still quite low in many emerging market economies, it is hard to know.
COVID-19 could have acquired higher transmissibility thanks to mutations that are in line with the progression from a pandemic to an endemic virus. This could mean that COVID-19 might be less virulent/lethal going forward, with roughly constant levels of infection and without major flareups. We may have to live with COVID-19 in the future, as we do with the current flu viral strains, but we will still have to closely monitor virus mutations, their virulence and immunity levels in the population.
Next Few Weeks Crucial
It is important to note that data about the clinical severity of, and the vaccine efficacy against, Omicron is rapidly evolving but still limited. This means the next few weeks will be crucial in terms of giving us a better idea about Omicron’s virulence and transmissibility. There will be media noise around the spread of the variant based on anecdotal experiences, which makes it imperative to focus on large, controlled data sets that separate signal from noise.
Even so, unlike the start of the pandemic, our healthcare systems ae better prepared to counter any new spread, be it in terms of the availability of COVID-19 self-tests, potential booster doses or our understanding of the science behind the virus’s spread. This means pharmaceutical companies will likely get quicker approval from the US Food and Drug Administration for the development and launch of new types of vaccines or booster dosages against the new variant.
Pfizer, for example, released study results that claim that its new anti-viral pill, Paxlovid, could cut the risk of hospitalization or death for patients at high risk of severe COVID-19 by 89% when patients are treated within three days following the appearance of symptoms. Similarly, over the next few weeks, drug companies will likely be releasing new data around the efficacy and durability of the current vaccines vis à vis Omicron, along with studies that have stress-tested different strains of the virus.
From a production perspective, assuming the logistics are in place, vaccines could be now rolled out globally at the rate of 1.0 to 1.5 billion doses per month for most of the strains. Eventually, we could be moving toward a situation where we might have to vaccinate against a new strain while herd immunity continues to build globally.
The emergence of Omicron will undoubtedly have some negative economic impact in the short term. However, it is occurring too late in the year for it to noticeably impact 2021 annual growth. It will also occur early enough in 2022 that there will be ample time for a compensatory bounce back after the likely hit to growth in Q1. For the time being, we have left our 2022 US growth forecast unchanged at 4.4%. However, we have trimmed our eurozone forecast by two tenths to 4.4%, although that is only tangentially due to Omicron.
The global growth forecast remains unchanged as well, at 4.6%, although we see some downside risks, primarily around China and emerging markets. Our 5.0% expectation for China’s 2022 growth is starting to look a bit generous, even with the recent easing policy bias.
More than Omicron, we are concerned about the massive hawkish tilt in the stance of developed market central banks this month. There is a high likelihood that the removal of accommodation accelerates and gathers critical mass just as economic growth moderates and inflationary pressures ease notably (in the latter part of 2022). With reduced excess savings, less support from inventory rebuilding, a slowdown in hiring (due to lack of workers) and softening housing demand, it would not take much to tip the US economy into a shallow technical recession in early 2023, regardless of Omicron.
Omicron has the potential to exacerbate the current cyclical dynamics that are at play. If the number of cases were to dramatically rise, amplifying the supply and demand dynamics that have developed over the last year, we could be staring at a higher or more persistent inflationary regime, which could push the Fed to an even more hawkish stance. This would amplify the anticipated deceleration in growth. Implications could include short-term rates moving higher and long-term rates moving lower, which suggest the possibility of a yield-curve inversion and a recessionary scenario where risk assets would tend to fare poorly (Figure 1).
Figure 1: US 5Y30Y Treasury Yield Curve Spread
The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without State Street Global Advisors’ express written consent.
The views expressed in this material are the views of Shalabh Gupta, Simona Mocuta and Matthew Nest through 20 December 2021 and are subject to change based on market and other conditions. This document contains certain statements that may be deemed forward looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected.
The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor's particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.
All information is from State Street Global Advisors unless otherwise noted and has been obtained from sources believed to be reliable, but its accuracy is not guaranteed. There is no representation or warranty as to the current accuracy, reliability or completeness of, nor liability for, decisions based on such information and it should not be relied on as such.
Past performance is not a guarantee of future results. Investing involves risk including the risk of loss of principal.
The trademarks and service marks referenced herein are the property of their respective owners. Third party data providers make no warranties or representations of any kind relating to the accuracy, completeness or timeliness of the data and have no liability for damages of any kind relating to the use of such data.
For EMEA Distribution: The information contained in this communication is not a research recommendation or ‘investment research’ and is classified as a ‘Marketing Communication’ in accordance with the Markets in Financial Instruments Directive (2014/65/EU) or applicable Swiss regulation. This means that this marketing communication (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This information is for informational purposes only, not to be construed as investment advice or a recommendation or offer to buy or sell any security. Investors should always obtain and read an up-to-date investment services description or prospectus before deciding whether to appoint an investment manager or to invest in a fund. Any views expressed herein are those of the author(s), are based on available information, and are subject to change without notice. Individual portfolio management teams may hold different views and may make different investment decisions for different clients. There are no guarantees regarding the achievement of investment objectives, target returns, portfolio construction, allocations or measurements such as alpha, tracking error, stock weightings and other information ratios. The views and strategies described may not be suitable for all investors. SSGA does not provide tax or legal advice. Prospective investors should consult with a tax or legal advisor before making any investment decision. Investing entails risks and there can be no assurance that SSGA will achieve profits or avoid incurring losses.
Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted.
Images of NYSE Group, Inc. are used with permission of NYSE Group, Inc. Neither NYSE Group, Inc. nor its affiliated companies sponsor, approve of or endorse the contents of this program. Neither NYSE Group, Inc. nor its affiliated companies recommend or make any representation as to possible benefits from any securities or investments.